Airwaves
| The first 150 words of the full text of this article appear below. |
As Casaburi points out in his accompanying editorial to the paper by Peters and colleagues, COPD is now recognised as distinctly not a disease of irreversible airflow obstruction. A number of pharmacological and non-pharmacological interventions have shown reduction of dyspnoea and improvement of exercise capacity, but we have little information on the additive effects of these therapies and, indeed, this is how they will be used in practice. In this issue of Thorax Peters and colleagues show, for the first time, additive effects on dyspnoea and exercise capacity of bronchodilator therapy and supplemental oxygen in normoxic COPD patients. Endurance time increased by 16% with bronchodilators compared with placebo, by 28% with oxygen alone, and by 40% with the combination of bronchodilator and oxygen compared with the endurance time achieved on room air and placebo. The paper also describes some interesting insights into the mechanisms of these improvements and sets the
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
